You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

54 Results
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Adjuvant
Nov 2023
Regimen
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Cancer Type:
Breast, 
Central Nervous System, 
Gastrointestinal, 
Colorectal, 
Esophagus, 
Gastric / Stomach, 
Hepatobiliary / Liver / Bile Duct, 
Pancreas, 
Genitourinary, 
Bladder / Urothelial, 
Prostate, 
Gynecologic, 
Cervix, 
Endometrial, 
Ovary, 
Head and Neck, 
Lung, 
Small Cell
Intent: Adjuvant, Curative, Palliative
Dec 2023
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Esophagus, 
Gastric / Stomach, 
Hepatobiliary / Liver / Bile Duct, 
Pancreas, 
Genitourinary, 
Bladder / Urothelial, 
Prostate, 
Head and Neck, 
Lung, 
Small Cell
Intent: Adjuvant
Dec 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Cancer Type:
Breast, 
Central Nervous System, 
Gastrointestinal, 
Colorectal, 
Esophagus, 
Gastric / Stomach, 
Hepatobiliary / Liver / Bile Duct, 
Pancreas, 
Genitourinary, 
Bladder / Urothelial, 
Prostate, 
Gynecologic, 
Cervix, 
Endometrial, 
Ovary, 
Head and Neck, 
Lung, 
Small Cell
Intent: Adjuvant, Curative, Palliative
Dec 2023
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab Emtansine - Adjuvant Treatment for Early Breast Cancer
Oct 2023
Regimen
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Apr 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Funding:
Exceptional Access Program
    osimertinib - For adjuvant therapy after tumour resection in patients with stage IB-IIIA (AJCC 7th edition, or equivalent) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858 R) substitution mutations
Dec 2023
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - Adjuvant Treatment for Renal Cell Carcinoma
Mar 2023

Pages